SEMA4D/CD100: As an Important Immunoregulator to Improve Immunotherapy
SEMA4D/CD100: As an Important Immunoregulator to Improve ImmunotherapyIn April 2022, the American Association for Cancer Research (AACR) annual meeting announced phase 1b/2 clinical data (NCT04815720) for Pepinemab, the first SEMA4D-targeted antibody for the treatment of recurrent or metas...
Detailed information

GUCY2C: a Novel Target in Tumor Immunotherapy, Specially in Colorectal Cancer CAR T Therapy!
GUCY2C: a Novel Target in Tumor Immunotherapy, Specially in Colorectal Cancer CAR T Therapy!On April 19, 2022, Innovative Cellular Therapeutics (ICT) company from Shanghai, China receives FDA Fast Track Designation for GCC19CART. GCC19CART is a CAR-T cell therapy based on ICT's unique CoupledCAR® technology pl...
Detailed information

ROR1, an Emerging Target for Tumor Immunotherapy
ROR1, an Emerging Target for Tumor ImmunotherapyIn 2020, the ROR1 target is favored by pharmaceutical giants such as Merck & Co., CStone Pharmaceuticals, etc. On October 29, 2020, Cstone Pharmaceuticals announced that it has reached a licensing agreement with LegoChem...
Detailed information

TFPI: a Natural Anticoagulant Protein, Future Therapies for Hemophilia
TFPI: a Natural Anticoagulant Protein, Future Therapies for HemophiliaEvery year, April 17 is observed as World Hemophilia Day. 17th April 2022 marks the observance of the 34rd World Hemophilia Day. Hemophilia is a general term for a group of rare bleeding disorders caused by an inherited ...
Detailed information

TTR: an Important Protein of Amyloidosis, Novel Therapies are Upcoming for Rare Diseases ATTR-CM and ATTR-PN!
TTR: an Important Protein of Amyloidosis, Novel Therapies are Upcoming for Rare Diseases ATTR-CM and ATTR-PN!AstraZeneca and Neurimmune Therapeutics have signed an agreement on Mar. 1, 2022, contributing about $700 million cooperation on NI006 clinical research. NI006 is a transthyretin (TTR) targeting modulator for rare diseas...
Detailed information

DT3C, a Powerful Tool for ADC Drug Internalization In Vitro
DT3C, a Powerful Tool for ADC Drug Internalization In VitroIn 2014, MikiYamaguchi et al. produced a recombinant protein through gene recombination technology, which is a tool to evaluate more precisely the efficiency of mAbs' internalization by cells. The protein includes a diph...
Detailed information

ANGPT2 (Ang-2): the First Bispecific Antibody for Eye Vision Loss Therapy, a Novel Target for Tumor Angiogenesis!
ANGPT2 (Ang-2): the First Bispecific Antibody for Eye Vision Loss Therapy, a Novel Target for Tumor Angiogenesis!On January 28, 2022, the FDA approved the first bispecific antibody Vabysmo (Ang-2 x VEGF-A) for eye, to treat two leading causes of vision loss--wet age-related macular degeneration (AMD) and diabetic macular edema (DME...
Detailed information

GPRC5D: Newly Efficient GPRC5D CAR-T or Bispecific Antibody Therapy to Fight Multiple Myeloma (MM)
GPRC5D: Newly Efficient GPRC5D CAR-T or Bispecific Antibody Therapy to Fight Multiple Myeloma (MM)The first GPRC5D CAR-T study from China (Identifier: NCT05219721), updated on ClinicalTrials.gov website (Feb. 2, 2022), has become a hot topic these days. The Phase I Trial of GPRC5D CAR-T started in Feb. 8, 2022, has b...
Detailed information

CXCR4: An Attractive Target of GPCR family Brings Promising New Drugs for Cancer Therapy!
CXCR4: An Attractive Target of GPCR family Brings Promising New Drugs for Cancer Therapy!BioLineRx Ltd presently has completed a successful pre-New Drug Application (NDA) meeting regarding a chemokine receptor CXCR4 antagonist (Motixafortide), from a report on January 18, 2022. In particular, the biopharmace...
Detailed information

The Collection of Progress of Anti-GPCR Antibody Drugs
The Collection of Progress of Anti-GPCR Antibody DrugsAs mentioned in the article entitled "G protein-Coupled Receptor - Targets for Drug Therapy", GPCRs is an important drug target, and currently about 40% of the marketed drugs are designed based on GPCRs. About 34% of dru...
Detailed information

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1